Fast-growing life sciences business Gentronix has been acquired by Danish business Scantox Group, marking a significant milestone for the company and its 70 employees.
Alderley Park-based Gentronix, a provider of genetic toxicology solutions to the global pharmaceutical, biotech, and agrichemical industries, was founded in 1999 by Prof. Richard Walmsley. In recent years, the company has experienced substantial growth, which has not gone unnoticed by Scantox Group. Headquartered in Ejby, south of Copenhagen, Scantox Group has recognised Gentronix for its high-quality genetic toxicology services and solid scientific engagement, serving a diverse and loyal global customer base.
Gentronix will maintain its current name and aims to broaden its offerings under Scantox, which is supported by Scandinavian investment company Impilo. Jeanet Løgsted, CEO of Scantox Group, expressed enthusiasm about the acquisition, stating, “I am thrilled that Scantox Group has been able to partner up with Gentronix. Genetic toxicology is a missing link in our portfolio and frequently requested by our clients to become a one-stop-shop premier CRO partner. Gentronix’s service line, client base, high-quality standards, and not least, people culture fit perfectly with our DNA. Our business plan is to continuously expand our service portfolio across all sites and add scientific excellence to the Group.”
Matt Tate, CEO of Gentronix, also commented on the acquisition, noting, “Becoming a part of Scantox Group is a fantastic next step for Gentronix, opening up unique possibilities for us to offer an even greater service portfolio to our clients. As an organisation, we look forward to collaborating with our new colleagues and continuing to support the delivery of world-leading contract research services to our customers. There is a strong strategic rationale in teaming up with Scantox and we have identified multiple commercial synergies.”
Nicholas Hooge, partner at Impilo, added, “We are thrilled to welcome Gentronix into the Scantox Group and see significant growth opportunities for the combined business going forward. 2024 is in many ways a transformational year for Scantox and this acquisition represents another important milestone in reaching Scantox’s strategic ambitions.”
The acquisition of Gentronix by Scantox represents a strategic expansion for both parties, promising new growth and enhanced capabilities in delivering genetic toxicology services on a global scale.
